A Framework for In Silico Clinical Trials for Medical Devices Using Concepts From Model Verification, Validation, and Uncertainty Quantification (VVUQ)

Author(s):  
Jeff Bodner ◽  
Vikas Kaul

Abstract The rising costs of clinical trials for medical devices in recent years has led to an increased interest in so-called in silico clinical trials, where simulation results are used to supplement or to replace those obtained from human patients. Here we present a framework for executing such a trial. This framework relies heavily on ideas already developed for model verification, validation, and uncertainty quantification. The framework uses results from an initial cohort of human patients as model validation data, recognizing that the best model credibility evidence usually comes from real patients. The validation exercise leads to an assessment of the model’s suitability based on pre-defined acceptance criteria. If the model meets these criteria, then no additional human patients are required and the study endpoints that can be addressed using the model are met using the simulation results. Conversely, if the model is found to be inadequate, it is abandoned, and the clinical study continues using only human patients in a second cohort. Compared to other frameworks described in the literature based on Bayesian methods, this approach follows a strict model build-validate-predict structure. It can handle epistemic uncertainties in the model inputs, which is a common trait of models of biomedical systems. Another idea discussed here is that the outputs of engineering models rarely coincide with measures that are the basis for clinical endpoints. This manuscript discusses how the link between the model and clinical measure can be established during the trial.

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Aldo Badano

AbstractImaging clinical trials can be burdensome and often delay patient access to novel, high-quality medical devices. Tools for in silico imaging trials have significantly improved in sophistication and availability. Here, I describe some of the principal advantages of in silico imaging trials and enumerate five lessons learned during the design and execution of the first all-in silico virtual imaging clinical trial for regulatory evaluation (the VICTRE study).


2021 ◽  
Vol 30 (8) ◽  
pp. 666-676
Author(s):  
Tatsuya Matsuda ◽  
Norihiko Ohura ◽  
Koji Mineta ◽  
Mami Ho ◽  
I Kaku ◽  
...  

In consultation with academia and the Pharmaceuticals and Medical Devices Agency (PMDA), we have developed guidance for drafting protocols for clinical trials concerning medical devices for the healing of hard-to-heal wounds without ischaemia. The guidance summarises the validity of single-arm trials for hard-to-heal wounds, the definition of hard-to-heal wounds without ischaemia, methods of patient enrolment and clinical endpoints. This review focuses on the logical thinking process that was used when establishing the guidance for improving the efficiency of clinical trials concerning medical devices for hard-to-heal wounds. We particularly focused on the feasibility of conducting single-arm trials and also tried to clarify the definition of hard-to-heal wounds. If the feasibility of randomised control trials is low, conducting single-arm trials should be considered for the benefit of patients. In addition, hard-to-heal wounds were defined as meeting the following two conditions: wounds with a wound area reduction <50% at four weeks despite appropriate standards of care; and wounds which cannot be closed by a relatively simple procedure (for example, suture, skin graft and small flaps). Medical devices for hard-to-heal wound healing are classified into two types: (1) devices for promoting re-epithelialisation; and (2) devices for improving the wound bed. For medical devices for promoting re-epithelialisation, we suggest setting complete wound closure, percent wound area reduction or distance moved by the wound edge as the primary endpoint in single-arm trials for hard-to-heal wounds. For medical devices for improving the wound bed, we suggest setting the period in which wounds can be closed by secondary intention or a simple procedure, such as the primary endpoint.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A Baretta ◽  
R Bursi ◽  
A Palazzin ◽  
L Emili

Abstract Introduction The absorption of radiofrequency (RF) energy during an MRI procedure may cause tissue heating in the vicinity of an implanted device, such as a stent or a stented valve, potentially causing patient harm. Computational modeling and simulation (M&S) can be used by medical device manufacturers to assess the RF-induced heating of implanted devices during an MRI scan and identify worst-case configurations within a given line of implants. However, despite the use of in-silico tools, a standard for in-silico testing of such problematic is still missing; The tool here proposed is a web-based application that automates the set-up and solution of RF-heating analysis, in line with existing standards for in-vitro testing. Methods The presented tool is part of a commercial web-based platform. The tool was developed in collaboration with the market leader of computer-aided engineering software and as part of a Research Collaboration Agreement with the American regulatory body. Commercial software was used to compute RF energy absorption and thermal heating of implantable medical devices replicating the directives of the ASTM F2182–11a Standard Test Method. The model is integrated in an automated workflow. Each simulation submitted by the user is sent to the cloud infrastructure for solution. Simulation results are stored in a database for later retrieval and report generation. Results The tool consists of a web-interface where the user can: i) upload the medical device computer-aided design (CAD) or select a simplified geometry from a library; ii) define the material properties of the device; ii) specify the desired input parameters specific to an MRI exposure scenario. Specifically, it is possible to study the device exposure: i) at different field frequencies (i.e., 64 MHz and 128 MHz); ii) at different powers (i.e., 2, 4 and 10 W/kg Whole body Specific Absorption Rate - SAR); iii) at different field polarizations (i.e., two circular and two linear); and iv) for different exposure time (i.e., form 240 s to 900 s). The presented tool allows the users to view and export results for each simulation, including electromagnetic fields, local SAR, and the temperature rise over time. Finally, the simulation results are summarized in an automatically generated report that follows regulatory guidance on M&S reporting. Conclusion The presented web-based M&S tool allows users to perform the thermal safety assessment of implantable medical devices during an MRI procedure following established good simulation practices. Minimal training or background in computer modeling is required to use the tool. Specific potential applications of the tool include RF-heating assessment of cardiovascular devices (e.g., stents, stented valves, stent retrievers). The proposed platform promotes the broader adoption of digital evidence in preclinical trials for RF safety analysis, supporting the device submission process and pre-market regulatory evaluation. Stent safety simulation result interface Funding Acknowledgement Type of funding source: None


2016 ◽  
Vol 3 (2) ◽  
pp. 37 ◽  
Author(s):  
Marco Viceconti ◽  
Adriano Henney ◽  
Edwin Morley-Fletcher

<p class="abstract">The term ‘in silico clinical trials indicates the use of individualised computer simulation in the development or regulatory evaluation of a medicinal product, medical device, or medical intervention. This review article summarises the research and technological roadmap developed by the Avicenna Support Action during an 18 month consensus process that involved 577 international experts from academia, the biomedical industry, the simulation industry, the regulatory world, etc. The roadmap documents early examples of in silico clinical trials, identifies relevant use cases for in silico clinical trial technologies over the entire development and assessment cycle for both pharmaceuticals and medical devices, identifies open challenges and barriers to a wider adoption and puts forward 36 recommendations for all relevant stakeholders to consider<span lang="EN-US">.</span></p>


2020 ◽  
Author(s):  
Abdelrahman H. Abdelmoneim ◽  
Safinaz I. Khalil ◽  
Hiba A. Osman ◽  
Ayesan Rewane ◽  
Sahar G. Elbage
Keyword(s):  

2021 ◽  
Author(s):  
Oisín Sean Byrne ◽  
Fergal Brian Coulter ◽  
Ellen T Roche ◽  
Eoin D O'Cearbhaill

Benchtop testing of endovascular medical devices under accurately simulated physiological conditions is a critical part of device evaluation prior to clinical assessment. Currently, glass, acrylic and silicone vascular models are...


2006 ◽  
Vol 47 (8) ◽  
pp. 1518-1521 ◽  
Author(s):  
Richard L. Popp ◽  
Beverly H. Lorell ◽  
Gregg W. Stone ◽  
Warren Laskey ◽  
John J. Smith ◽  
...  

2010 ◽  
Vol 61 (4) ◽  
pp. 825-839 ◽  
Author(s):  
H. Hauduc ◽  
L. Rieger ◽  
I. Takács ◽  
A. Héduit ◽  
P. A. Vanrolleghem ◽  
...  

The quality of simulation results can be significantly affected by errors in the published model (typing, inconsistencies, gaps or conceptual errors) and/or in the underlying numerical model description. Seven of the most commonly used activated sludge models have been investigated to point out the typing errors, inconsistencies and gaps in the model publications: ASM1; ASM2d; ASM3; ASM3 + Bio-P; ASM2d + TUD; New General; UCTPHO+. A systematic approach to verify models by tracking typing errors and inconsistencies in model development and software implementation is proposed. Then, stoichiometry and kinetic rate expressions are checked for each model and the errors found are reported in detail. An attached spreadsheet (see http://www.iwaponline.com/wst/06104/0898.pdf) provides corrected matrices with the calculations of all stoichiometric coefficients for the discussed biokinetic models and gives an example of proper continuity checks.


Sign in / Sign up

Export Citation Format

Share Document